Neurofibromatosis 2 in the pediatric population

Journal of Child Neurology

Volumn 18, Issue 10, 2003, Pages 718-724

  Nunes, Fabio ^a   MacCollin, Mia ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOUSTIC NEURINOMA; CLINICAL EXAMINATION; CONTROLLED STUDY; CRANIAL NEUROPATHY; DIAGNOSTIC PROCEDURE; FAMILY HISTORY; GENETIC ANALYSIS; HEARING IMPAIRMENT; HEARING LOSS; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENINGIOMA; MOBILIZATION; NEUROFIBROMATOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SPINAL CORD TUMOR; SURGICAL TECHNIQUE; TUMOR VOLUME; VISUAL IMPAIRMENT;

EID: 0242708725     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738030180101301     Document Type: Review

References (20)

1. Mulvihill JJ, Parry DM, Sherman JL, et al: NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990;113:39-52.
2. Baser ME, Friedman JM, Wallace AJ, et al: Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59: 1759-1765.
3. Evans DGR, Huson SM, Donnai D, et al: A clinical study of type 2 neurofibromatosis. QJM 1992;84:603-618.
4. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al: Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52: 450-461.
5. Mautner VF, Lindenau M, Baser ME, et al: The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996; 38:880-886.
6. MacCollin M, Mautner VF: The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 1998; 5: 243-252.
7. Evans DGR, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999;81:496-499.
8. Kluwe L, Friedrich RE, Hagel C, et al: Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors. J Invest Dermatol 2000;114:1017-1021.
9. Ragge NK, Baser ME, Riccardi VM, Falk RE: The ocular presentation of neurofibromatosis 2. Eye 1997; 11 (Pt 1): 12-18.
10. Kluwe L, Friedrich RE, Tatagiba M, Mautner VF: Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: A method based on tumor analysis. Genet Med 2002;4(1):27-30.
11. Samii M, Matthies C, Tatagiba M: Management of vestibular schwannomas (acoustic neuromas): Auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997;40: 696-705.
12. Brackmann DE, Fayad JN, Slattery WH 3rd, et al: Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 2001;49:274-280.
13. Kluwe L, Mautner V, Parry DM, et al: The parental origin of new mutations in neurofibromatosis 2. Neurogenetics 2000;3(1):17-24.
14. Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al: Germ-line mutations in the neurofibromatosis 2 gene: Correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59: 529-539.
15. Mautner VF, Lindenau M, Baser ME, et al: Skin abnormalities in neurofibromatosis 2. Arch Dermatol 1997; 133:1539-1543.
16. Baser MJ, Friedman JM, Aeschliman D, et al: Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002;71: 715-723.
17. Ruttledge MH, Andermann AA, Phelan CM, et al: Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-342.
18. Zucman-Rossi J, Legoix P, Der Sarkissian H, et al: NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 1998;7:2095-2101.
19. Kluwe L, Mautner V, Heinrich B, et al: Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40:109-114.
20. Mautner VF, Tatagiba M, Guthoff R, et al: Neurofibromatosis 2 in the pediatric age group. Neurosurgery 1993;33:92-96.